MX2017001862A - Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b. - Google Patents
Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.Info
- Publication number
- MX2017001862A MX2017001862A MX2017001862A MX2017001862A MX2017001862A MX 2017001862 A MX2017001862 A MX 2017001862A MX 2017001862 A MX2017001862 A MX 2017001862A MX 2017001862 A MX2017001862 A MX 2017001862A MX 2017001862 A MX2017001862 A MX 2017001862A
- Authority
- MX
- Mexico
- Prior art keywords
- triazinones
- prophylaxis
- hepatitis
- treatment
- virus infection
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invencion proporciona nuevos compuestos que tienen la formula general (ver formula) en donde R1, R2, R3, X y a son como se describen en la descripcion y en las reivindicaciones, asi como sus sales farmaceuticamente aceptables. La invencion tambien contiene composiciones que incluyen los compuestos y metodos para utilizar los compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014084356 | 2014-08-14 | ||
| PCT/EP2015/068406 WO2016023877A1 (en) | 2014-08-14 | 2015-08-11 | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001862A true MX2017001862A (es) | 2017-05-15 |
Family
ID=53836080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001862A MX2017001862A (es) | 2014-08-14 | 2015-08-11 | Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9902701B2 (es) |
| EP (1) | EP3180319B1 (es) |
| JP (1) | JP6506836B2 (es) |
| KR (1) | KR101891933B1 (es) |
| CN (1) | CN106573898B (es) |
| BR (1) | BR112017002970B1 (es) |
| CA (1) | CA2952541C (es) |
| MX (1) | MX2017001862A (es) |
| RU (1) | RU2664329C1 (es) |
| WO (1) | WO2016023877A1 (es) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG186830A1 (en) | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| LT3785717T (lt) | 2015-09-16 | 2022-04-11 | Gilead Sciences, Inc. | Coronaviridae infekcijų gydymo būdai |
| CA3014369A1 (en) | 2016-02-19 | 2017-08-24 | Novartis Ag | Tetracyclic pyridone compounds as antivirals |
| US10179792B2 (en) | 2016-03-07 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11738013B2 (en) | 2016-05-27 | 2023-08-29 | Gilead Sciences, Inc. | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| DK3526323T3 (da) | 2016-10-14 | 2023-06-26 | Prec Biosciences Inc | Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet |
| US20190256474A1 (en) * | 2016-10-26 | 2019-08-22 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| WO2018083106A1 (en) | 2016-11-03 | 2018-05-11 | F. Hoffmann-La Roche Ag | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN110088104B (zh) | 2016-11-03 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物 |
| CN109863145B (zh) | 2016-11-03 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的新的四氢异喹啉和四氢二氮杂萘化合物 |
| AU2017353986B2 (en) | 2016-11-07 | 2021-08-19 | Arbutus Biopharma Corporation | Substituted pyridinone-containing tricyclic compounds, and methods using same |
| WO2018087345A1 (en) | 2016-11-14 | 2018-05-17 | F. Hoffmann-La Roche Ag | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON |
| AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| AR111419A1 (es) | 2017-04-27 | 2019-07-10 | Novartis Ag | Compuestos fusionados de indazol piridona como antivirales |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| BR112020004112A2 (pt) | 2017-08-28 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | agentes antiviras da hepatite b |
| US11267825B2 (en) | 2017-11-02 | 2022-03-08 | Aicuris Gmbh & Co. Kg | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) |
| KR20200083552A (ko) | 2017-11-02 | 2020-07-08 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드 |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP2021507906A (ja) | 2017-12-20 | 2021-02-25 | ノバルティス アーゲー | 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| SG11202007646UA (en) | 2018-02-13 | 2020-09-29 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| TWI826492B (zh) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| JP7460644B2 (ja) | 2018-10-31 | 2024-04-02 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物 |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| JP2022506351A (ja) | 2018-11-02 | 2022-01-17 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規ウレア６，７－ジヒドロ－４ｈ－チアゾロ［５，４－ｃ］ピリジン |
| AR116948A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| UY38436A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| AU2020231115A1 (en) | 2019-03-07 | 2021-08-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| MX2021013085A (es) | 2019-04-30 | 2021-11-17 | Aicuris Gmbh & Co Kg | Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb). |
| BR112021021652A2 (pt) | 2019-04-30 | 2021-12-21 | Aicuris Gmbh & Co Kg | Oxalil piperazinas inovadoras ativas contra o vírus da hepatite b (hbv) |
| AU2020265390A1 (en) | 2019-04-30 | 2021-12-23 | Aicuris Gmbh & Co. Kg | Novel phenyl and pyridyl ureas active against the hepatitis B virus (HBV) |
| JP2022533007A (ja) | 2019-04-30 | 2022-07-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のインドリジン－２－カルボキサミド |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
| TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
| AU2021234308C1 (en) | 2020-03-12 | 2024-02-22 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| CN115996928A (zh) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
| WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| WO2022046631A1 (en) | 2020-08-24 | 2022-03-03 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
| TW202233204A (zh) | 2020-08-27 | 2022-09-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
| TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| US20230000873A1 (en) | 2021-05-26 | 2023-01-05 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US20230212199A1 (en) | 2021-08-18 | 2023-07-06 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| CN114057650B (zh) * | 2021-11-08 | 2023-03-28 | 温州大学 | 一种一锅法制备4,5-二氢哒嗪-3-酮类化合物的方法 |
| CN114349707B (zh) * | 2022-01-20 | 2024-01-09 | 中国医学科学院医药生物技术研究所 | 一种n-取代脲类化合物及其制备方法和应用 |
| WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| TW202345786A (zh) | 2022-03-02 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| WO2023168194A1 (en) | 2022-03-03 | 2023-09-07 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20230382940A1 (en) | 2022-03-03 | 2023-11-30 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| WO2023239665A1 (en) | 2022-06-06 | 2023-12-14 | Gilead Sciences, Inc. | Methods for treatment of viral infections including sars-cov-2 |
| WO2024006376A1 (en) | 2022-06-29 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20240043466A1 (en) | 2022-06-30 | 2024-02-08 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD286354A5 (de) | 1989-08-08 | 1991-01-24 | Karl-Marx-Universitaet Leipzig,De | Verfahren zur herstellung substituierter 2-carbamoyl-methyl-4-phenyl-1,2,5,6-tetrahydro- und 1,2-dihydro-1-oxo-pyridazine |
| SI1070056T1 (en) | 1998-03-14 | 2004-12-31 | Altana Pharma Ag | Phthalazinone pde iii/iv inhibitors |
| CA2484631A1 (en) * | 2002-05-13 | 2003-11-27 | Merck & Co., Inc. | Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles |
| GB0507575D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| EP2019830A4 (en) * | 2006-05-04 | 2011-01-19 | Inst Hepatitis & Virus Res | INHIBITORS OF THE SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR THE TREATMENT OF A CHRONIC HEPATITIS VIRUS |
| WO2008016239A1 (en) | 2006-08-02 | 2008-02-07 | Lg Life Sciences Ltd. | Caspase inhibitors based on pyridazinone scaffold |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| KR20120059530A (ko) * | 2009-08-07 | 2012-06-08 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 살진균성 다이페닐-치환된 피리다진 |
| WO2012047856A2 (en) * | 2010-10-04 | 2012-04-12 | Institute For Hepatitis And Virus Research | Novel inhibitors of secretion of hepatitis b virus antigens |
| CN102964340B (zh) | 2012-12-12 | 2015-10-07 | 中国药科大学 | 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂 |
| US8937178B2 (en) | 2013-03-13 | 2015-01-20 | Flatley Discovery Lab | Phthalazinone compounds and methods for the treatment of cystic fibrosis |
-
2015
- 2015-08-11 WO PCT/EP2015/068406 patent/WO2016023877A1/en active Application Filing
- 2015-08-11 MX MX2017001862A patent/MX2017001862A/es active IP Right Grant
- 2015-08-11 JP JP2017507954A patent/JP6506836B2/ja active Active
- 2015-08-11 CA CA2952541A patent/CA2952541C/en active Active
- 2015-08-11 CN CN201580042241.5A patent/CN106573898B/zh active Active
- 2015-08-11 RU RU2017105878A patent/RU2664329C1/ru active
- 2015-08-11 EP EP15750039.8A patent/EP3180319B1/en active Active
- 2015-08-11 BR BR112017002970-7A patent/BR112017002970B1/pt active IP Right Grant
- 2015-08-11 KR KR1020177003911A patent/KR101891933B1/ko active IP Right Grant
-
2017
- 2017-02-14 US US15/432,706 patent/US9902701B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3180319B1 (en) | 2018-10-03 |
| EP3180319A1 (en) | 2017-06-21 |
| CN106573898B (zh) | 2018-11-09 |
| CA2952541C (en) | 2019-10-01 |
| KR101891933B1 (ko) | 2018-08-24 |
| WO2016023877A1 (en) | 2016-02-18 |
| BR112017002970B1 (pt) | 2023-04-11 |
| RU2664329C1 (ru) | 2018-08-16 |
| CA2952541A1 (en) | 2016-02-18 |
| US20170157133A1 (en) | 2017-06-08 |
| KR20170029602A (ko) | 2017-03-15 |
| JP2017524015A (ja) | 2017-08-24 |
| CN106573898A (zh) | 2017-04-19 |
| BR112017002970A2 (pt) | 2018-01-30 |
| US9902701B2 (en) | 2018-02-27 |
| JP6506836B2 (ja) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001862A (es) | Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b. | |
| MX2016014728A (es) | Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b. | |
| PH12016501254A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
| PH12015502443A1 (en) | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| MY188114A (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| PH12016501379A1 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| PH12017501258B1 (en) | Pyrazine compounds for the treatment of infectious diseases | |
| MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
| PH12015500347A1 (en) | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| EA201690979A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| MX2018008095A (es) | Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih. | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2015015691A (es) | Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion del virus sincital respiratorio. | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| MX2017000312A (es) | Derivados de isoindolina para usarse en el tratamiento de una infeccion viral. | |
| MX2016001855A (es) | Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio. | |
| WO2018039077A8 (en) | Therapeutic compounds | |
| MX2016001858A (es) | Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio. | |
| MX2016009250A (es) | Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |